09/04/2026
🐇💉✨ **GLITTER GREMLIN RABBIT HOLE: THE PEPTIDE GOLD RUSH**
Well, kids.
Apparently we’ve entered the **PEPTIDE GOLD RUSH.** 💉💰
And before anybody gets their peptide panties in a wad:
# # # **I LIKE PEPTIDES.**
😂
Peptides are fascinating.
Some are established medicines.
Some have legitimate human clinical data.
Some are being actively investigated for very interesting potential uses.
And some have approximately **three mice, an enthusiastic podcast, and a waiting list.**
Those are not all the same thing.
But lately I’ve become fascinated by something other than the molecules themselves:
# # # **The BUSINESS of peptides.**
Because I recently listened to a presentation about entering the peptide business.
And some of the advice was...
Well.
Glitter Gremlin's eyebrow may never return to its normal position.
👁️👄👁️
Among the statements made during the presentation:
💰 **“Peptides are the best place to start.”**
💰 **“You don't need to know how it works; the product will speak for itself.”**
💰 **“No work. Just buy inventory and they work.”**
💰 **“Huge, huge, huge demand.”**
And when describing what you need to get started:
📦 **Inventory.**
🏷️ **A label.**
💳 **The ability to collect payment.**
📬 **The ability to ship.**
Ummmmmmmm.
Did we perhaps leave something off the shopping list?
😂
Because Glitter Gremlin would like to add:
🔬 **UNDERSTANDING WHAT THE F**K YOU'RE SELLING.**
I know.
I'm difficult like that.
Now, to be fair, the presenter ALSO acknowledged that there are regulatory issues, that quality matters, that people need guidance, and that getting this wrong can get you into trouble.
Good.
Because those things matter.
But then came the business opportunity.
A relationship had been negotiated with a supplier/pharmacy.
There was training on regulatory issues, packaging, what to say and what NOT to say, marketing, etc.
The training cost?
💰 **$2,500.**
And after completing it?
💉 **A $2,500 credit toward inventory.**
Because apparently even peptides have discovered the **starter-pack business model.**
😂💀
And THIS is where I want to separate two conversations that are getting mashed together all over the wellness world.
# # # Conversation #1:
**Are peptides scientifically interesting?**
HELL YES.
Many peptides interact with very specific receptors and signaling pathways.
Some have become enormously important medicines.
Others are producing intriguing early research.
There is absolutely legitimate science here.
# # # Conversation #2:
**Does the existence of legitimate peptide science mean every peptide being marketed for healing, longevity, fat loss, anti-aging, recovery, cognition, muscle growth or whatever Tuesday's miracle happens to be has established clinical efficacy?**
HELL NO.
💉😂
That's not how evidence works.
A mechanism is not a clinical outcome.
An animal study is not a human trial.
A promising early human study is not definitive evidence.
A testimonial is not a controlled trial.
And:
# # # **“They just work if you get it right” is not a clinical endpoint.**
Neither is:
# # # **“Everybody wants them.”**
Neither is:
# # # **“The margins are great.”**
And neither is:
# # # **“We can't keep them in stock.”**
Those may be excellent descriptions of a **market**.
They are not descriptions of **clinical evidence.**
And that's what bothers me about the Gold Rush mentality.
When demand explodes faster than knowledge, suddenly the questions become:
💰 How much inventory should I buy?
💰 What's my margin?
💰 How do I market it?
💰 How quickly can I launch?
💰 How do I ship it?
And Glitter Gremlin is standing in the back of the room waving both arms:
# # # 🔬 **WHAT DOES THE F**KING PEPTIDE DO?!**
😂😂😂
Which peptide?
At what dose?
For which patient?
For what indication?
Through what route?
Based on what human evidence?
What outcome are we expecting?
What are the risks?
What do we monitor?
What do we know about long-term use?
And perhaps most importantly:
# # # **WHAT DON'T WE KNOW YET?**
Because saying **“we don't know yet”** isn't anti-peptide.
It's science.
I don't want emerging medicine stopped.
I want MORE research.
I want better trials.
I want better manufacturing.
I want clinicians exploring promising therapies responsibly.
I want researchers chasing weird molecules down weird rabbit holes.
Hell, I'll probably be standing beside them holding the flashlight.
🐇🔦😂
But there's a gigantic difference between:
# # # **“This is promising. Let's investigate it.”**
and
# # # **“Buy inventory. They work. Demand is huge.”**
One is scientific curiosity.
The other sounds suspiciously like somebody discovered a gold mine.
And history has taught us something about gold rushes:
# # # **The people selling the shovels usually do pretty damn well.** 💰⛏️
So yes.
Study peptides.
Use evidence where we have it.
Explore emerging evidence where we don't.
Ask questions.
Follow the research.
But if somebody tells you that you **don't even need to understand how the product works** before you start selling it...
Glitter Gremlin has officially entered the chat.
👁️👄👁️💉
Because my patients deserve better than:
# # # **BUY. LABEL. SHIP.**
They deserve:
# # # **KNOW. THINK. QUESTION. THEN TREAT.** 🔬❤️
That's considerably less sexy than a Gold Rush.
But it's a hell of a lot closer to medicine.
— **Dr. Heather McGhee, DNP, APRN, FNP-C**
✨ **The Glitter Gremlin**
**P.S. “Huge demand” is not a mechanism of action. 💉💰😂🔬✨**
Send a message to learn more